Background: A malfunction in the melanocortin-4 receptor (MC4R) is associated with obesity in rare genetic syndromes; setmelanotide is a new drug that activates this receptor and is being used to treat severe obesity. This meta-analysis evaluated the efficacy and safety of setmelanotide for weight loss in severe obesity linked to human MC4R deficiency.

Methods: We searched PubMed, Embase, and Cochrane for randomized and nonrandomized clinical trials using setmelanotide. We considered a -value ≤ 0.05 statistically significant.

Results: We included 376 patients, of whom 328 (87.2%) received setmelanotide for a mean follow-up of 52 weeks. The mean age was 32.8 (14.67) years. Weight loss was significant (MD -3.52; 95% CI -3.98, -3.05; = 0.01; I = 92%), with an average proportion of -6.91% weight loss during treatment. Changes in BMI showed an MD of -10.55 kg/m in patients > 18 years and -0.61 kg/m in patients < 18 years (BMI score). However, the drug was associated with a higher risk of skin hyperpigmentation (OR 0.69; 95% CI 0.55, 0.80; = 0.08).

Conclusions: Our results support the use of setmelanotide in treating severe obesity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608339PMC
http://dx.doi.org/10.3390/jpm13101460DOI Listing

Publication Analysis

Top Keywords

severe obesity
12
weight loss
12
efficacy safety
8
safety setmelanotide
8
melanocortin-4 receptor
8
kg/m patients
8
patients years
8
setmelanotide
6
setmelanotide melanocortin-4
4
receptor agonist
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!